TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21183747

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline mean arterial pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline pulse pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline blood pressure variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline blood pressure parameters
Number of subjects: 0
Study: 18644685

Group type: EXPERIMENTAL
Intervention: Naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for 11 weeks, plus sertraline 50 mg once daily for 2 weeks, followed by 100 mg once daily for 10 weeks
Number of subjects: 113

Group type: COMPARATOR
Intervention: Naltrexone 12.5 mg once daily for 3 days, 25 mg once daily for 4 days, and 50 mg once daily for 11 weeks, plus placebo sertraline
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Naltrexone with sertraline
Number of subjects: 113

Group type: COMPARATOR
Intervention: Naltrexone with placebo
Number of subjects: 113
Study: 17875198

Group type: EXPERIMENTAL
Intervention: Acupuncture + proton pump inhibitor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Doubling the proton pump inhibitor dose
Number of subjects: 30
Study: 14734123

Group type: EXPERIMENTAL
Intervention: Darusentan (mean dose 144 +/- 125 mg/day, dosages of 30 mg, 100 mg, or 300 mg for 3 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11452711

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 14
Study: 9756581

Group type: EXPERIMENTAL
Intervention: Therapist-supervised, 8-week, 3-times-per-week, home-based exercise program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care as prescribed by the patients' physicians
Number of subjects: 20
Study: 7809773

Group type: COMPARATOR
Intervention: Detergent, Metsan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metsan combined with acaricide, Acarosan
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 60
Study: 3107600

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study: 29389738

Group type: EXPERIMENTAL
Intervention: ramipril 10 mg od
Number of subjects: 59

Group type: COMPARATOR
Intervention: doxazosin 8 mg od
Number of subjects: 59
Study: 27437724

Group type: EXPERIMENTAL
Intervention: Active music therapy (AMT) plus standard of care (SC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 30
Study: 25743829

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant chemotherapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: High-frequency microsatellite instability without adjuvant chemotherapy
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: High-frequency microsatellite instability
Number of subjects: 460
Study: 23246249

Group type: EXPERIMENTAL
Intervention: 7-day course of oral doxycycline (Doxy-7)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14-day course of oral doxycycline (Doxy-14)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (Doxy-7 and Doxy-14)
Number of subjects: 40
Study: 21444113

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 600 mg/d)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 18193917

Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapy (Allopurinol + Probenecid)
Number of subjects: 12
Study: 16552508

Group type: EXPERIMENTAL
Intervention: Multidetector CT enteroclysis (MDCT‐E)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Barium enteroclysis with methylcellulose (BE)
Number of subjects: 52
Study: 12612033

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 10 ms interval between median nerve stimulation and TMS pulse.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with a 25 ms interval between median nerve stimulation and TMS pulse.
Number of subjects: 0

Group type: COMPARATOR
Intervention: PAS(10 ms) under the influence of dextromethorphan (an NMDA receptor antagonist).
Number of subjects: 0

Group type: COMPARATOR
Intervention: PAS(10 ms) under the influence of nimodipine (an L-type voltage-gated calcium-channel antagonist).
Number of subjects: 0
Study: 11028833

Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg) daily for 28 days
Number of subjects: 30
Study: 8649631

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) - enoxaparin 40 mg/0.4 ml
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1335012

Group type: EXPERIMENTAL
Intervention: Physical training and placebo tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once a day and inactivity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Physical training and atenolol 50 mg once a day
Number of subjects: 12
Study: 6724794

Group type: EXPERIMENTAL
Intervention: Glycerol (7.5 g in a 25% solution before meals)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Glucose (placebo, same amount as glycerol)
Number of subjects: 31
Study: 31262317

Group type: COMPARATOR
Intervention: Postal follow-up
Number of subjects: 2074

Group type: COMPARATOR
Intervention: Online follow-up
Number of subjects: 2074

Group type: COMPARATOR
Intervention: Telephone follow-up
Number of subjects: 2074

Group type: EXPERIMENTAL
Intervention: Face-to-face follow-up
Number of subjects: 2074
Study: 28582271

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate (CHO) loading (800 mL of water containing 100 g of CHO)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo (800 mL of water)
Number of subjects: 880
Study: 27427996

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 20 U
Number of subjects: 225
Study: 24656402

Group type: EXPERIMENTAL
Intervention: Contrast medium (CM) enhanced MRI
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Contrast medium (CM) enhanced CT
Number of subjects: 716

Group type: COMPARATOR
Intervention: Control group (no contrast)
Number of subjects: 716
Study: 22370487

Group type: EXPERIMENTAL
Intervention: Expanded workplace depression treatment programs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment for major depressive disorder (MDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Detection and treatment of depression among patients with chronic physical disorders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early MDD treatment interventions
Number of subjects: 0
Study: 20852963

Group type: EXPERIMENTAL
Intervention: [¹H]MRSI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of [¹H]MRSI and DCE-MRI
Number of subjects: 150
Study: 17656179

Group type: EXPERIMENTAL
Intervention: Peer education and clinic-based counseling promoting use of male and female condoms
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Nonuse of effective contraceptives and self-reported unprotected sex
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: Pregnancy outcomes
Number of subjects: 935
Study: 15813810

Group type: EXPERIMENTAL
Intervention: Nasal steroids (budesonide 400 microg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Specific allergen immunotherapy (SIT)
Number of subjects: 41
Study: 12154417

Group type: EXPERIMENTAL
Intervention: GIK solution therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: OP‐CAB surgery
Number of subjects: 44
Study: 10217079

Group type: EXPERIMENTAL
Intervention: Screening with CA 125 and ultrasonography
Number of subjects: 21935

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 21935

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21935
Study: 8682006

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (Balke protocol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (Bruce and Steep protocols)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (Ellestad protocol)
Number of subjects: 16
Study: 2136113

Group type: EXPERIMENTAL
Intervention: Observer reports of abstinence
Number of subjects: 0
Study: 727414

Group type: EXPERIMENTAL
Intervention: 0.5-1.0% halothane
Number of subjects: 28

Group type: COMPARATOR
Intervention: 50 microgram fentanyl/kg
Number of subjects: 28
Study: 31245903

Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Ivor‐Lewis surgery
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Sweet surgery
Number of subjects: 434
Study: 27841795

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: gemcitabine
Number of subjects: 0
Study: 26164314

Group type: EXPERIMENTAL
Intervention: Lid debridement‐scaling (LDS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no LDS)
Number of subjects: 14
Study: 23835764

Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 2

Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 2
Study: 21673685

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 2034

Group type: COMPARATOR
Intervention: FOLFOX4 (5‐fluorouracil/folinic acid plus oxaliplatin)
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: XELOX/XELOX‐placebo/XELOX‐bevacizumab arms
Number of subjects: 2034

Group type: COMPARATOR
Intervention: FOLFOX4/FOLFOX4‐placebo/FOLFOX4‐bevacizumab arms
Number of subjects: 2034

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 2034
Study: 19250295

Group type: EXPERIMENTAL
Intervention: Comprehensive school‐based preventive oral health program
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Basic preventive program
Number of subjects: 1748

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Remote schools
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Children with black stain
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Children without black stain
Number of subjects: 1748

Group type: EXPERIMENTAL
Intervention: Children with and without black stain
Number of subjects: 1748
Study: 18162029

Group type: EXPERIMENTAL
Intervention: EE/DRSP (ethinyl estradiol 30 mug/day plus drospirenone 3 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: EE (ethinyl estradiol 30 mug/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15358970

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner
Number of subjects: 406

Group type: COMPARATOR
Intervention: Physician
Number of subjects: 406
Study: 11800061

Group type: EXPERIMENTAL
Intervention: Eprosartan, 600‐800 mg once daily
Number of subjects: 334

Group type: COMPARATOR
Intervention: Enalapril, 5‐20 mg once daily
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 334

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 334
Study: 9840406

Group type: EXPERIMENTAL
Intervention: High sodium intake (HNa), 348.4 mmol x day(‐1), n=7
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Moderate sodium intake (MNa), 174.1 mmol x day(‐1), n=9
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low sodium intake (LNa), 66.3 mmol x day(‐1), n=9
Number of subjects: 25

Group type: COMPARATOR
Intervention: All conditions (HNa, MNa, LNa)
Number of subjects: 25
Study: 8037128

Group type: EXPERIMENTAL
Intervention: Atrioventricular junction radiofrequency ablation plus pacemaker therapy (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pacemaker therapy alone (n = 11)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atrioventricular junction radiofrequency ablation
Number of subjects: 23
Study: 2725928

Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31432080

Group type: EXPERIMENTAL
Intervention: Postsurgical electrical stimulation (PES) following surgery for severe cubital tunnel syndrome, 1 hour of 20 Hz PES after surgery.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group received cubital tunnel surgery and sham stimulation.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Postsurgical electrical stimulation (PES) following surgery for severe cubital tunnel syndrome.
Number of subjects: 31
Study: 30080726

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 108
Study: 29063853

Group type: EXPERIMENTAL
Intervention: Brachytherapy plus External Beam Radiation Therapy (EBRT)
Number of subjects: 5836

Group type: COMPARATOR
Intervention: Brachytherapy alone
Number of subjects: 5836

Group type: EXPERIMENTAL
Intervention: Brachytherapy plus EBRT (favorable intermediate-risk)
Number of subjects: 5836

Group type: COMPARATOR
Intervention: Brachytherapy alone (favorable intermediate-risk)
Number of subjects: 5836

Group type: EXPERIMENTAL
Intervention: Brachytherapy plus EBRT (unfavorable intermediate-risk)
Number of subjects: 5836

Group type: COMPARATOR
Intervention: Brachytherapy alone (unfavorable intermediate-risk)
Number of subjects: 5836

Group type: EXPERIMENTAL
Intervention: Brachytherapy plus EBRT (high-risk)
Number of subjects: 5836

Group type: COMPARATOR
Intervention: Brachytherapy alone (high-risk)
Number of subjects: 5836
Study: 25970794

Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: OrthoMTA
Number of subjects: 102

Group type: COMPARATOR
Intervention: ProRoot MTA
Number of subjects: 102
Study: 23064441

Group type: EXPERIMENTAL
Intervention: 10 mg/kg TXA immediately before CS
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (no TXA)
Number of subjects: 174
Study: 22192368

Group type: EXPERIMENTAL
Intervention: everolimus DES
Number of subjects: 50

Group type: COMPARATOR
Intervention: everolimus BVS
Number of subjects: 50
Study: 19262394

Group type: EXPERIMENTAL
Intervention: Hyperpronation
Number of subjects: 66

Group type: COMPARATOR
Intervention: Supination-flexion
Number of subjects: 66
Study: 17304419

Group type: EXPERIMENTAL
Intervention: Ultrathin-walled two-stage twin endotracheal tube (UTTS-T-ETT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional endotracheal tube (ETT)
Number of subjects: 28
Study: 12930275

Group type: EXPERIMENTAL
Intervention: EVCPP with CABG (group I, n = 14)
Number of subjects: 22

Group type: COMPARATOR
Intervention: CABG only (group II, n = 8)
Number of subjects: 22
Study: 11140366

Group type: EXPERIMENTAL
Intervention: Energy drink (caffeine, taurine, glucuronolactone)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9109749

Group type: EXPERIMENTAL
Intervention: Xanomeline high dose (225 mg)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Xanomeline (dose-dependent)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 8225682

Group type: EXPERIMENTAL
Intervention: 400 mcg b.i.d. misoprostol
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3512420

Group type: EXPERIMENTAL
Intervention: oral acyclovir alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: oral acyclovir plus co‐trimoxazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo plus co‐trimoxazole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole
Number of subjects: 40
Study: 31633746

Group type: EXPERIMENTAL
Intervention: Systematic depression screening with notification of primary care clinicians and provision of centralized, patient-preference, stepped depression care for those with positive screening results (n=499)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Systematic depression screening with notification of primary care clinicians for those with positive screening results (n=501)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Usual care (no screening) (n=500)
Number of subjects: 1500
Study: 30646140

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 86017

Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 86017

Group type: EXPERIMENTAL
Intervention: Cox-adjusted analysis for CEA
Number of subjects: 86017

Group type: EXPERIMENTAL
Intervention: Propensity-matched analysis for CEA
Number of subjects: 86017

Group type: EXPERIMENTAL
Intervention: Instrumental variable analysis for CEA
Number of subjects: 86017
Study: 27282261

Group type: EXPERIMENTAL
Intervention: PPI plus rebamipide (300 mg/day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: PPI monotherapy (10 mg/day)
Number of subjects: 130
Study: 25035199

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard fractionation (SFX) to 70 Gy in 35 fractions given once a day
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HFX)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard fractionation (SFX)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HFX) and Standard fractionation (SFX)
Number of subjects: 250
Study: 22787053

Group type: EXPERIMENTAL
Intervention: MABT5102A (MABT), a humanized anti-Aβ monoclonal antibody of IgG4 isotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MABT5102A (MABT)
Number of subjects: 0
Study: 20019086

Group type: EXPERIMENTAL
Intervention: Docetaxel-gemcitabine (DG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vinorelbine-cisplatin (VC)
Number of subjects: 0
Study: 18936396

Group type: EXPERIMENTAL
Intervention: long‐pulsed 755‐nm alexandrite laser (12‐mm spot size)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: long‐pulsed 755‐nm alexandrite laser (18‐mm spot size)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: long‐pulsed 1064‐nm Nd:YAG laser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of long‐pulsed 1064‐nm Nd:YAG laser and long‐pulsed 755‐nm alexandrite laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 20
Study: 15821526

Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg tablets
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 12819976

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no photodynamic therapy)
Number of subjects: 25
Study: 10532139

Group type: EXPERIMENTAL
Intervention: Mebendazole (100 mg every 12 hours for three days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nitazoxanide (100 mg every 12 hours for three days)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nitazoxanide
Number of subjects: 82
Study: 8752779

Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg before surgical incision (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pentazocine 60 mg before surgical incision (group A)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pentazocine 30 mg after abdominal incision (group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pentazocine 60 mg after abdominal incision (group B)
Number of subjects: 46
Study: 1833105

Group type: EXPERIMENTAL
Intervention: Fish oil extract (total EPA dose of 2.4 g/day) for 6 weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (olive oil) for 6 weeks
Number of subjects: 6
Study: 7096142

Group type: EXPERIMENTAL
Intervention: NH4Cl (300 mg/kg body wt) to induce acidosis
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NaHCO3 to induce alkalosis
Number of subjects: 6

Group type: COMPARATOR
Intervention: CaCO3 as placebo
Number of subjects: 6
Study: 31428434

Group type: EXPERIMENTAL
Intervention: Relaxation programme
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 36
Study: 30596708

Group type: EXPERIMENTAL
Intervention: Baseline neutrophil counts >3500 cells/mm3
Number of subjects: 801

Group type: COMPARATOR
Intervention: Baseline neutrophil counts ≤1000 cells/mm3
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Time-updated neutrophil count
Number of subjects: 801
Study: 26957103

Group type: EXPERIMENTAL
Intervention: Cedar Project WelTel mHealth intervention (mobile phone, cellular plan, weekly two-way text messaging, support from Cedar Case Managers)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cedar Project WelTel mHealth intervention
Number of subjects: 200
Study: 25031230

Group type: EXPERIMENTAL
Intervention: Normothermia (skin temperature ≈34°C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperthermia (+1.2 ± 0.1°C increase in internal temperature, skin temperature ≈39°C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LBNP tolerance during hyperthermia
Number of subjects: 10
Study: 22349946

Group type: COMPARATOR
Intervention: Ethanol treatment for 0s (control group) with Adper™ Scotchbond™ Multi‐Purpose (Scotchbond)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ethanol treatment for 20s (Group 1) with hydrophobic adhesive
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ethanol treatment for 60s (Group 2) with hydrophobic adhesive
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ethanol treatment for three 60s periods (Group 3) with hydrophobic adhesive
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stepwise ethanol application (Group 4) with hydrophobic adhesive
Number of subjects: 5
Study: 20831571

Group type: EXPERIMENTAL
Intervention: 30-minute music intervention for 4 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Rest period for 4 weeks (Control)
Number of subjects: 66
Study: 17714101

Group type: EXPERIMENTAL
Intervention: Drug therapies for neuropathic pain
Number of subjects: 0
Study: 16227728

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation of the soft palate
Number of subjects: 88